Last reviewed · How we verify
NCT06151171
Pharmacokinetics of Different CoQ10 Formulations
NA trial testing CoQ10 in Coenzyme Q10 Pharmacokinetics in 15 participants. Completed in 31 October 2022.
31 October 2022
Quick facts
| Lead sponsor | Factors Group of Nutritional Companies Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 March 2022 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 October 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- CoQ10 — full drug profile →
Conditions studied
- Coenzyme Q10 Pharmacokinetics — all drugs for Coenzyme Q10 Pharmacokinetics →
Sponsor
Factors Group of Nutritional Companies Inc. — full company profile →
Who can join
Adults 21 to 65, any sex, with Coenzyme Q10 Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this trial is to compare the bioavailability (AUC, Tmax, and Cmax) of different Coenzyme Q10 preparations in healthy adults. Pharmacokinetic parameters of orally ingested CoQ10 such as AUC, Cmax and Tmax, as well as the ratio of reduced CoQ10 levels to total CoQ10 plasma levels (using the AUC) after administration are compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06151171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CoQ10
Trials testing the same drug.
- NCT06419335 — Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study · EARLY_PHASE1 · active not recruiting
- NCT05422534 — CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease · Phase 3 · recruiting
- NCT03579693 — Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease · Phase 2 · completed
- NCT03968640 — Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients · Phase 3 · withdrawn
- NCT03133793 — CoQ10 and D-ribose in Patients With Diastolic Heart Failure · Phase 2 · completed
Other Factors Group of Nutritional Companies Inc. trials
Trials by the same sponsor.
- NCT06202157 — Metabolic Differences Between Dihydroberberine and Micellar Berberine · NA · completed
- NCT06345950 — Pharmacokinetics and Safety of a New Micellar Glutathione Formulation · NA · completed
- NCT05394701 — Comparing the Pharmacological Profile of Formulations Containing Omega 3 Fatty Acids · NA · completed
- NCT05370261 — Pharmacological Profile of Different Berberine Formulations, and Effects on Blood Sugar Levels · NA · completed
- NCT05611827 — Pharmacological Profile of Different Quercetin Formulations · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06151171 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Factors Group of Nutritional Companies Inc.
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing